96 related articles for article (PubMed ID: 38555869)
1. Leveraging the Fragment Length of Circulating Tumour DNA to Improve Molecular Profiling of Solid Tumour Malignancies with Next-Generation Sequencing: A Pathway to Advanced Non-invasive Diagnostics in Precision Oncology?
Underhill HR
Mol Diagn Ther; 2021 Jul; 25(4):389-408. PubMed ID: 34018157
[TBL] [Abstract][Full Text] [Related]
2. Current and future genomic applications for surgeons.
Alkhatib O; Miles T; Jones RP; Mair R; Palmer R; Winter H; McDermott FD
Ann R Coll Surg Engl; 2024 Apr; 106(4):321-328. PubMed ID: 38555869
[TBL] [Abstract][Full Text] [Related]
3. Serial monitoring of genomic alterations in circulating tumor cells of ER-positive/HER2-negative advanced breast cancer: feasibility of precision oncology biomarker detection.
Cani AK; Dolce EM; Darga EP; Hu K; Liu CJ; Pierce J; Bradbury K; Kilgour E; Aung K; Schiavon G; Carroll D; Carr TH; Klinowska T; Lindemann J; Marshall G; Rowlands V; Harrington EA; Barrett JC; Sathiyayogan N; Morrow C; Sero V; Armstrong AC; Baird R; Hamilton E; Im SA; Jhaveri K; Patel MR; Dive C; Tomlins SA; Udager AM; Hayes DF; Paoletti C
Mol Oncol; 2022 May; 16(10):1969-1985. PubMed ID: 34866317
[TBL] [Abstract][Full Text] [Related]
4. Implications for the colorectal surgeon following the 100 000 Genomes Project.
McDermott FD; Newton K; Beggs AD; Clark SK
Colorectal Dis; 2021 May; 23(5):1049-1058. PubMed ID: 33471415
[TBL] [Abstract][Full Text] [Related]
5. Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer.
Chung JH; Pavlick D; Hartmaier R; Schrock AB; Young L; Forcier B; Ye P; Levin MK; Goldberg M; Burris H; Gay LM; Hoffman AD; Stephens PJ; Frampton GM; Lipson DM; Nguyen DM; Ganesan S; Park BH; Vahdat LT; Leyland-Jones B; Mughal TI; Pusztai L; O'Shaughnessy J; Miller VA; Ross JS; Ali SM
Ann Oncol; 2017 Nov; 28(11):2866-2873. PubMed ID: 28945887
[TBL] [Abstract][Full Text] [Related]
6. Circulating Tumor DNA as a Minimal Residual Disease Assessment and Recurrence Risk in Patients Undergoing Curative-Intent Resection with or without Adjuvant Chemotherapy in Colorectal Cancer: A Systematic Review and Meta-Analysis.
Chidharla A; Rapoport E; Agarwal K; Madala S; Linares B; Sun W; Chakrabarti S; Kasi A
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373376
[TBL] [Abstract][Full Text] [Related]
7. Circulating tumour DNA in metastatic breast cancer to guide clinical trial enrolment and precision oncology: A cohort study.
Zivanovic Bujak A; Weng CF; Silva MJ; Yeung M; Lo L; Ftouni S; Litchfield C; Ko YA; Kuykhoven K; Van Geelen C; Chandrashekar S; Dawson MA; Loi S; Wong SQ; Dawson SJ
PLoS Med; 2020 Oct; 17(10):e1003363. PubMed ID: 33001984
[TBL] [Abstract][Full Text] [Related]
8. Individualized cancer vaccines versus surveillance after adjuvant chemotherapy for surgically resected high-risk stage 2 and stage 3 colorectal cancer: protocol for a randomized trial.
Jones RP; Lee LYW; Corrie PG; Danson S; Vimalachandran D
Br J Surg; 2023 Nov; 110(12):1883-1884. PubMed ID: 37856683
[No Abstract] [Full Text] [Related]
9. Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial.
Kirkwood JM; Del Vecchio M; Weber J; Hoeller C; Grob JJ; Mohr P; Loquai C; Dutriaux C; Chiarion-Sileni V; Mackiewicz J; Rutkowski P; Arenberger P; Quereux G; Meniawy TM; Ascierto PA; Menzies AM; Durani P; Lobo M; Campigotto F; Gastman B; Long GV
Nat Med; 2023 Nov; 29(11):2835-2843. PubMed ID: 37845511
[TBL] [Abstract][Full Text] [Related]
10. UK-BioNTech partnership for mRNA cancer vaccines.
Wilkinson E
Lancet Oncol; 2023 Aug; 24(8):846. PubMed ID: 37454666
[No Abstract] [Full Text] [Related]
11. Multi-cancer early detection test in symptomatic patients referred for cancer investigation in England and Wales (SYMPLIFY): a large-scale, observational cohort study.
Nicholson BD; Oke J; Virdee PS; Harris DA; O'Doherty C; Park JE; Hamady Z; Sehgal V; Millar A; Medley L; Tonner S; Vargova M; Engonidou L; Riahi K; Luan Y; Hiom S; Kumar H; Nandani H; Kurtzman KN; Yu LM; Freestone C; Pearson S; Hobbs FR; Perera R; Middleton MR
Lancet Oncol; 2023 Jul; 24(7):733-743. PubMed ID: 37352875
[TBL] [Abstract][Full Text] [Related]
12. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer.
Rojas LA; Sethna Z; Soares KC; Olcese C; Pang N; Patterson E; Lihm J; Ceglia N; Guasp P; Chu A; Yu R; Chandra AK; Waters T; Ruan J; Amisaki M; Zebboudj A; Odgerel Z; Payne G; Derhovanessian E; Müller F; Rhee I; Yadav M; Dobrin A; Sadelain M; Łuksza M; Cohen N; Tang L; Basturk O; Gönen M; Katz S; Do RK; Epstein AS; Momtaz P; Park W; Sugarman R; Varghese AM; Won E; Desai A; Wei AC; D'Angelica MI; Kingham TP; Mellman I; Merghoub T; Wolchok JD; Sahin U; Türeci Ö; Greenbaum BD; Jarnagin WR; Drebin J; O'Reilly EM; Balachandran VP
Nature; 2023 Jun; 618(7963):144-150. PubMed ID: 37165196
[TBL] [Abstract][Full Text] [Related]
13. Personalised therapeutic approaches to glioblastoma: A systematic review.
Mowforth OD; Brannigan J; El Khoury M; Sarathi CIP; Bestwick H; Bhatti F; Mair R
Front Med (Lausanne); 2023; 10():1166104. PubMed ID: 37122327
[TBL] [Abstract][Full Text] [Related]
14. Clinical advances and ongoing trials on mRNA vaccines for cancer treatment.
Lorentzen CL; Haanen JB; Met Ö; Svane IM
Lancet Oncol; 2022 Oct; 23(10):e450-e458. PubMed ID: 36174631
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
